Haemonetics (NYSE:HAE) announced that the FDA cleared advancements to its NexSys PCS plasma collection system.
Enhancements include a new plasma collection bowl and new Express Plus technology, according to a news release. The bowl features a patented design to optimize performance and Express Plus reduces procedure time.
Boston-based Haemonetics designed NexSys PCS as a completely integrated system for streamlining plasma collection. It improves yield, productivity, safety, quality, compliance and donor satisfaction. The latest advancements should produce an average procedure time of between 33 and 38 minutes, the company said. It should help customers achieve new levels of plasma center efficiency and lower costs to collect.
Haemonetics says NexSys PCS with NexLynk DMS donor management software already delivers a 16-minute reduction in donor door-to-door time. With Persona technology, it delivers between 9% and 12% additional plasma yield by personalizing collections to individual donor characteristics. Haemonetics plans for an initial market release for the advancements in the coming months.
“Haemonetics sets the standard in global plasma collection solutions that meet collectors’ most critical needs. With our redesigned bowl and new Express Plus technology for faster procedure times and enhanced plasma center efficiency, we continue to advance our innovation to lead the industry in reducing cost per liter for collectors and ensuring the best experience for their donors,” said Roy Galvin, president, Global Plasma and Blood Center at Haemonetics.